Hilleman Laboratories announces strategic collaboration with Gotovax AB to develop next generation Oral Cholera Vaccine
Aims to offer OCVs at a significantly more affordable price than the ones currently available in the market for developing countries
:: First-of-its-kind partnership undertaken to address unmet needs of the Cholera disease burden in highly endemic areas like Bengal delta, Africa
:: Demand for vaccine is expected to sharply increase in Cholera endemic countries
:: Hilleman Laboratories’ thermostability technology to facilitate stockpiling in diverse geographies
New Delhi, June 17, 2014: Hilleman Laboratories, an equal joint-venture partnership between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation, today announces its strategic collaboration with Gotovax AB, a University of Gothenburg spin-off biopharmaceutical company, to develop a high impact Oral Cholera Vaccine. With this collaboration, Hilleman Laboratories aims to deliver the vaccine at a significantly more affordable price than the ones currently available in the market. Easy to administer, with cross protection against ETEC diarrhea and enhanced with a longer shelf life; this vaccine candidate will be most suited for geographies with the highest cholera burden like Africa and South Asia.
“Cholera is endemic in over 50 countries with estimated mortality of 100,000-120,000 deaths and a morbidity of 3.8-4.4 million annual cases attributed to this disease. There is an urgent need of highly effective and affordable Cholera vaccines both for outbreaks as well as mass vaccination campaigns. Our partnership with Gotovax AB is carefully aligned to Hilleman Laboratories’ core philosophy of addressing unmet health needs of the underprivileged by developing accessible and innovative vaccines which are affordable,” said Dr. Davinder Gill, CEO, Hilleman Laboratories…